Cardiac amyloidosis red flags: What all the cardiologist have to know

IF 1.9 Q3 PERIPHERAL VASCULAR DISEASE
Alessandro Maloberti , Claudio Ciampi , Francesco Politi , Saverio Fabbri , Francesco Musca , Cristina Giannattasio
{"title":"Cardiac amyloidosis red flags: What all the cardiologist have to know","authors":"Alessandro Maloberti ,&nbsp;Claudio Ciampi ,&nbsp;Francesco Politi ,&nbsp;Saverio Fabbri ,&nbsp;Francesco Musca ,&nbsp;Cristina Giannattasio","doi":"10.1016/j.ijcrp.2024.200271","DOIUrl":null,"url":null,"abstract":"<div><p>Cardiac amyloidosis is becoming increasingly important among cardiologist and an early diagnosis is very important. Amyloidosis is a systemic disease and many cardiac and extracardiac elements (red flags) should raise the suspicion of the disease. Electrocardiographic and imaging techniques (such as echocardiography, cardiac magnetic resonance and scintigraphy) are useful tools to make a diagnosis together with the presence of orthopedic issues, peripheral neuropathy or plasma cell dyscrasia. Cardiac amyloidosis is also often associated with valvular disorder, heart failure or cardiomyopathy. Red flags are crucial to raise suspicion and reach an early diagnosis, in order to start a targeted treatment strategy that could change the patient's outcome. Indeed, in the last years four new drugs were approved to treat transthyretin amyloidosis.</p></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"21 ","pages":"Article 200271"},"PeriodicalIF":1.9000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772487524000369/pdfft?md5=82695930583ce0e9b5824df165f8db8f&pid=1-s2.0-S2772487524000369-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Cardiology Cardiovascular Risk and Prevention","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772487524000369","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

Cardiac amyloidosis is becoming increasingly important among cardiologist and an early diagnosis is very important. Amyloidosis is a systemic disease and many cardiac and extracardiac elements (red flags) should raise the suspicion of the disease. Electrocardiographic and imaging techniques (such as echocardiography, cardiac magnetic resonance and scintigraphy) are useful tools to make a diagnosis together with the presence of orthopedic issues, peripheral neuropathy or plasma cell dyscrasia. Cardiac amyloidosis is also often associated with valvular disorder, heart failure or cardiomyopathy. Red flags are crucial to raise suspicion and reach an early diagnosis, in order to start a targeted treatment strategy that could change the patient's outcome. Indeed, in the last years four new drugs were approved to treat transthyretin amyloidosis.

心脏淀粉样变性红旗:心脏病医生必须知道的事情
心脏淀粉样变性在心脏病专家中的地位日益重要,早期诊断非常重要。淀粉样变性是一种全身性疾病,许多心脏和心脏外因素(红旗)都应引起对该疾病的怀疑。心电图和成像技术(如超声心动图、心脏磁共振和闪烁照相)以及骨科疾病、周围神经病变或浆细胞异常是诊断的有用工具。心脏淀粉样变性还常常伴有瓣膜病、心力衰竭或心肌病。红旗是引起怀疑和早期诊断的关键,以便开始有针对性的治疗策略,从而改变患者的预后。事实上,在过去几年中,已经有四种治疗转甲状腺素淀粉样变性病的新药获得批准。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.00
自引率
0.00%
发文量
0
审稿时长
72 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信